Financial Exploitation of Elders in Massachusetts: The Most Common Form of Abuse and the Civil Claims It Produces
Physical elder abuse draws more public attention, but financial exploitation is the most prevalent form of elder abuse in the United States and the form least likely to be reported. An older adult who is defrauded by a family member, a caregiver, or a financial advisor loses not only money but often the independence that […]
How to Navigate a Claim for Loss of Life
Losing a family member to a sudden accident changes your world in a single heartbeat. You are left managing unimaginable grief while facing a mountain of unexpected financial stress. Funeral bills arrive, household income suddenly drops, and the administrative burdens of closing out a loved one’s affairs can feel entirely overwhelming. It is an incredibly […]
Headaches After a Car Accident: What Causes Them, Why They Are Legally Significant, and How to Document Them
Post-traumatic headaches are one of the most common symptoms following a car accident and one of the most legally complicated to pursue in a personal injury claim. They are common in the general population independent of trauma, making the causation argument vulnerable to the defense assertion that the headaches predate the crash or are unrelated […]
Stealth BioTherapeutics Appoints David A. Brown, Ph.D., as Chief Scientific Officer

Brown brings more than 20 years of experience in mitochondrial research and scientific team leadership.
First Implant of KingstronBio’s ProStyle M® Transcatheter Mitral Valve System Successfully Completed in National Multicenter Confirmatory Study

On March 12, 2026, the first implant of the ProStyle M® Transcatheter Mitral Valve System (ProStyle M®) was successfully completed under pure ultrasound guidance as part of its confirmatory clinical study. The device is independently developed by KingstronBio Technology (Changshu) Co., Ltd. (KingstronBio). The procedure was performed by Professor Wang Chunsheng and Professor Wei Lai of […]
Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock
Company Appoints D. Keith Grossman to Board of Directors
BD Delivers Next‑Generation TIPS Innovation to Advance Portal Hypertension Care Across the European Union

CE Marking and ARCH clinical trial data position the Liverty™ TIPS Stent Graft to expand treatment options for patients with advanced liver disease
Finding Common Regulatory Ground in AIs Growing Role within Pharmacovigilance | By: Anuradha (Annie) Prabhakar, Associate Director, Product Management, Vigilance Detect, IQVIA

Pharmacovigilance has traditionally required organizations to balance the urgency of reporting with the rigor of accurately detecting adverse event and product complaints. AI has the potential to ease this burden by enabling earlier pre‑signal identification, automated detection, faster case processing and expanded surveillance across both structured and unstructured data
Variational AI Releases Enki 4: Major Update to Foundation Model for Small-Molecule Drug Discovery
Variational AI introduces Enki™ 4: an improved algorithm and architecture designed to scale, expanding the pre-trained target coverage from 592 to 760 and now applicable to proximity-based therapeutics and novel payloads for antibody drug conjugates
The Frontline of Patient Care: Rethinking Medical Clinic Waiting Room Safety
Equipping these frontline workers with comprehensive first aid and CPR in Ottawa ensures that every clinic operates with a seamless, highly prepared safety protocol from the very moment a patient walks through the front door.
Bailey & Galyen Signs Multi-Million Dollar Deal as Choctaw Stadium’s Exclusive Legal Sponsor
The new partnership builds on a relationship between Bailey & Galyen in Mansfield TX and the Texas Rangers since 2022, when the firm first became the club’s official legal sponsor.
Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
Mechanism-Driven Study Design Focused on Capital Efficiency and Accelerated Development for Near-Term Value Creation, Addressing a $2 Billion Potential Target Market